Pharmacognosy intro
Black seed's pharmacological depth centers on thymoquinone (TQ), a benzoquinone monoterpene present at 0.5-3.5% of seed and 18-25% of the volatile oil, supported by thymohydroquinone, p-cymene (7-15% of volatile oil), alpha-pinene, nigellone (dithymoquinone), the unique indazole alkaloids nigellidine and nigellicine, and a rich fixed oil fraction (30-40% seed weight) dominated by linoleic and oleic acids. Premium preparations achieve 3-5% TQ via supercritical CO2 extraction, with cymene/thymoquinone chemotype classification verified across cultivation regions. Thymoquinone operates through dual NF-kappaB inhibition: it blocks IKKbeta-mediated phosphorylation and degradation of IkappaBalpha to prevent NF-kappaB nuclear translocation, and directly inhibits NF-kappaB DNA binding activity, while also activating PPAR-gamma for further NF-kappaB transcriptional suppression. TQ simultaneously inhibits both cyclooxygenase and lipoxygenase enzyme pathways, reducing synthesis of pro-inflammatory prostaglandins and leukotrienes. Antioxidant enzyme regulation includes upregulation of SOD, catalase, and glutathione peroxidase with reduced lipid peroxidation markers. Clinical meta-analyses demonstrate significant fasting plasma glucose reduction (-9.93 mg/dL), HbA1c reduction (-0.57%), and improvements in lipid profiles. A randomized controlled trial showed 500 mg BID Nigella sativa oil capsules significantly reduced DAS-28 scores in rheumatoid arthritis patients.